Core Viewpoint - Cathay Securities has initiated coverage on China Biologic Products (01177) with a "Buy" rating and a target price of HKD 10, forecasting earnings per share of RMB 0.293, RMB 0.259, and RMB 0.283 for the years 2025 to 2027 respectively [1] Group 1: Industry Overview - The investment sentiment in the healthcare sector in mainland China has significantly rebounded over the past year, positioning China Biologic Products favorably within this trend [1] - The company is recognized as one of the largest and best-developed pharmaceutical enterprises in China, with strong capabilities in scale, financing, and commercial infrastructure [1] Group 2: Company Strategy and Development - The company has increased its investment in business development (BD) to rapidly expand its portfolio of innovative drugs [1] - There is potential for external licensing in the short term, with several key catalysts and possible product approvals on the horizon that could add new value to its innovative pipeline [1] - Important clinical data is expected to be released soon, which is likely to accelerate the progress of innovative research and development [1]

Core Viewpoint - Cathay Securities has initiated coverage on China Biologic Products (01177) with a "Buy" rating and a target price of HKD 10, forecasting earnings per share of RMB 0.293, 0.259, and 0.283 for the years 2025 to 2027 respectively [1] Group 1: Industry Overview - The investment sentiment in the healthcare sector in mainland China has significantly rebounded over the past year, positioning China Biologic Products favorably within this trend [1] - The company is recognized as one of the largest and best-developed pharmaceutical enterprises in China, with strong capabilities in scale, financing, and commercial infrastructure [1] Group 2: Company Strategy and Development - China Biologic Products has increased its investment in business development, rapidly expanding its portfolio of innovative drugs [1] - The company is expected to have several key catalysts and potential product approvals on the horizon, which will add new value to its innovative pipeline [1] - Important clinical data is anticipated to be released soon, which is likely to accelerate the progress of its innovative research and development [1]

Group 1 - The core viewpoint is that the collaboration between China and the US in innovation is expected to continue, with a recovery in domestic innovation and R&D demand in China [1][2] - The MSCI China Healthcare Index has increased by 74.0% since the beginning of 2025, outperforming the MSCI China Index by 37.3% [1] - The price for experimental monkeys, essential for innovative drug R&D, has risen from approximately 85,000 yuan in mid-2024 to about 90,000 yuan [1] Group 2 - China's rich pool of engineers and scientists, along with efficient and cost-effective clinical trials and drug manufacturing capabilities, are seen as core competitive advantages for pharmaceutical innovation [2] - The impact of the US imposing tariffs on innovative drugs is expected to be limited for the CXO sector, as many multinational pharmaceutical companies already have plans to build factories in the US [2] - Future growth in innovative drugs is anticipated to be driven by overseas partners pushing clinical development for licensed pipelines [2]

Group 1 - The core viewpoint is that the collaboration between China and the US in innovation is expected to continue, with a recovery in domestic innovation and R&D demand in China [1][2] - The MSCI China Healthcare Index has increased by 74.0% since the beginning of 2025, outperforming the MSCI China Index by 37.3% [1] - The price for experimental monkeys, essential for innovative drug R&D, has risen from approximately 85,000 yuan in mid-2024 to about 90,000 yuan [1] Group 2 - The US is expected to impose tariffs on innovative drugs, but the impact on the CXO sector is anticipated to be limited [2] - Trump's announcement on September 25 states that unless pharmaceutical companies are building factories in the US, patented drugs will face a 100% tariff starting October 1 [2] - The continuous upward momentum for innovative drugs is expected to primarily come from overseas partners pushing clinical developments for authorized pipelines [2]

Core Viewpoint - The MSCI China Healthcare Index has increased by 74.0% year-to-date, outperforming the MSCI China Index by 37.3% [1] Group 1: Market Trends - The recovery in capital market financing and the increase in overseas trading scale for innovative drugs have led to a rebound in domestic innovative drug research and development demand [1] - The CXO industry is expected to see performance recovery in the second half of the year due to the impact of U.S. interest rate cuts [1] Group 2: Regulatory Impact - The anticipated increase in tariffs on innovative drugs by the U.S. is expected to have a limited impact on the CXO sector [1] - Many multinational pharmaceutical companies already have plans to establish factories in the U.S., which may mitigate potential negative effects [1] Group 3: Future Outlook - The ongoing upward momentum for innovative drugs is expected to primarily come from overseas partners driving clinical progress for authorized pipelines [1] - There is optimism regarding valuation recovery opportunities in consumer healthcare, with recommendations to buy stocks in companies such as 3SBio, Junshi Biosciences, WuXi AppTec, Genscript Biotech, China National Pharmaceutical Group, and Innovent Biologics [1]

Market Overview - Global markets showed mixed performance, with the Hang Seng Index down 1.35% and the S&P 500 up 0.59% year-to-date performance for the Hang Seng Index stands at 30.25% [1][2] - The Chinese stock market saw declines, particularly in the technology, healthcare, and consumer discretionary sectors, while essential consumer goods, energy, and financials experienced gains [3] Industry Insights - The Chinese pharmaceutical industry is witnessing a recovery in domestic innovation research and development demand, with the MSCI China Healthcare Index up 74.0% since early 2025, outperforming the MSCI China Index by 37.3% [4] - The demand for early-stage research is showing positive signs, supported by a resurgence in capital market financing and a favorable environment for biotech innovation [9] - The CXO industry is expected to see performance recovery in the second half of 2025 due to increased demand for early-stage research and development [4][9] Company Analysis - WuXi AppTec (药明康德) is maintaining a strong growth trajectory in its TIDES business, with plans to expand peptide production capacity significantly by the end of 2025 [8] - The company reported a 14.5% year-on-year increase in new orders for preclinical services in the first half of 2025, with a notable 19.9% increase from U.S. clients [9] - WuXi AppTec's management is confident in maintaining resilient profitability, with adjusted gross and net profit margins reaching historical highs of 44.5% and 30.4% respectively in the first half of 2025 [10]

Group 1 - The core viewpoint of the reports indicates a recovery in domestic innovative drug research and development due to the resurgence of capital market financing and an increase in overseas transactions for innovative drugs [1] - The price of experimental monkeys, essential for innovative drug research, has risen from approximately 85,000 yuan in mid-2024 to about 90,000 yuan [1] - The CXO industry is expected to see performance recovery in the second half of 2025, driven by the continuous upward momentum of innovative drugs primarily from overseas partners pushing clinical pipelines [1] Group 2 - The report highlights a shift in global early-stage drug innovation research from Europe and the US to China, with multinational pharmaceutical companies increasingly sourcing innovative pipelines from Chinese biotech firms [1] - The proposed administrative order by the Trump administration to restrict the import of experimental treatments from China has sparked intense lobbying from two opposing groups: US biotech investors facing competition from Chinese innovations and large pharmaceutical companies benefiting from low-cost Chinese drugs [1] - The report emphasizes that the income and profit scale of large US pharmaceutical companies far exceed that of US biotech firms, suggesting they may have greater lobbying influence [1] Group 3 - The announcement of a 100% tariff on patented drugs unless pharmaceutical companies build factories in the US is expected to have a limited impact on the CXO sector, as many multinational companies already have plans to establish facilities in the US [2] - Significant investment plans have been announced by several multinational pharmaceutical companies for building factories and R&D facilities in the US, including Eli Lilly's $27 billion and Roche's $50 billion investments over the next five years [2] - The report notes that the construction of factories in the US typically takes over five years, and the progress may be affected by political and market uncertainties [2]

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in the next 12 months [2][30]. Core Insights - The MSCI China Healthcare Index has increased by 74.0% since the beginning of 2025, outperforming the MSCI China Index, which rose by 37.3% [1]. - There is a recovery in domestic demand for innovative drug research and development, driven by a resurgence in capital market financing and an increase in the scale of innovative drug transactions abroad [1]. - The price for experimental monkeys, essential for innovative drug research, has risen from approximately 85,000 yuan in mid-2024 to about 90,000 yuan [1]. - The CXO industry is expected to see performance recovery in the second half of 2025 due to the impact of U.S. interest rate cuts [1]. Summary by Sections Industry Overview - The report anticipates that U.S.-China innovation cooperation will continue, despite differing opinions in the U.S. [4]. - The global pharmaceutical innovation pipeline is shifting from Western biotech firms to Chinese biotech companies [4]. - Major multinational pharmaceutical companies are investing significantly in U.S. facilities, which may mitigate the impact of proposed tariffs on innovative drugs [4]. Company Recommendations - The report recommends buying shares in the following companies: - 三生制药 (Sangfor) [2] - 巨子生物 (Giant Biotech) [2] - 药明合联 (WuXi AppTec) [2] - 固生堂 (Gushengtang) [2] - 中国生物制药 (China National Pharmaceutical) [2] - 信达生物 (Innovent Biologics) [2] Market Trends - The report highlights that the continuous rise in innovative drugs will primarily come from overseas partners pushing clinical pipelines that have been licensed [4]. - There is optimism regarding the valuation recovery opportunities in consumer healthcare [4].

Group 1 - Tencent Holdings (00700) leads the net inflow with 2.642 billion, representing a 22.29% increase in share price [1][2] - Sunac China Holdings (00412) follows with a net inflow of 889 million, but its share price decreased by 6.00% [1][2] - SMIC (00981) has a net inflow of 684 million, with a share price increase of 5.72% [1][2] Group 2 - Hong Kong Exchanges and Clearing (00388) experiences the highest net outflow at -351 million, with a slight share price increase of 0.18% [1][2] - ZTE Corporation (00763) has a net outflow of -299 million, with a share price decrease of 0.18% [1][2] - China Biologic Products Holdings (01177) sees a net outflow of -210 million, with a share price decline of 1.72% [1][2] Group 3 - Weilu Group (01196) has the highest net inflow ratio at 68.77% [1][3] - Jiangsu Nanjing Highway (00177) follows with a net inflow ratio of 62.76% [1][3] - Air China (00753) ranks third with a net inflow ratio of 54.19% [1][3] Group 4 - Guangzhou-Shenzhen Railway (00525) has the highest net outflow ratio at -50.24% [1][3] - China Unicom (00762) follows with a net outflow ratio of -41.90% [1][3] - China Telecom (00728) ranks third with a net outflow ratio of -35.91% [1][3]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4][6]. Core Viewpoints - The report emphasizes that the Chinese pharmaceutical industry has completed the transition from old to new growth drivers, particularly highlighting the significant potential of innovative drugs. The report suggests that the industry is expected to rebound in the second half of 2025, driven by innovation and the aging population [53][54]. Summary by Sections Industry Performance - From September 22 to September 26, the pharmaceutical index fell by 2.20%, underperforming the CSI 300 index by 3.27%. The report notes a significant adjustment in small-cap stocks since August, but anticipates a stabilization and rebound in innovative drugs due to upcoming catalysts such as ESMO and BD meetings [5][34]. Company Focus: Xinlitai - Xinlitai has made significant strides in its innovative research and development, particularly in the cardiovascular-kidney-metabolism (CKM) chronic disease area. The company has a comprehensive pipeline covering hypertension, dyslipidemia, heart failure, and metabolic diseases, with multiple products already in clinical stages [3][9][15]. - The company’s innovative drug revenue accounted for 58% of its total drug revenue in the first half of 2025, indicating a strong shift towards innovation-driven growth [9][30]. Investment Recommendations - The report recommends focusing on companies that are well-positioned in the innovative drug sector, such as Xinlitai, Healer Pharmaceutical, and others. It also highlights the importance of companies with improving performance and low valuation levels, particularly in the CXO and supply chain sectors [6][53][54]. Market Trends - The report identifies several key trends driving the pharmaceutical industry, including the acceleration of aging demographics, the growth of chronic disease demand, and the increasing importance of innovative drugs in the market. It also notes that the healthcare payment system is evolving to support these trends [53][54]. Performance of Individual Stocks - The report lists top-performing stocks during the week, with Xinlitai showing a 16% increase. Conversely, it notes significant declines in stocks like Borui Pharmaceutical, which fell by 38% [34][36]. Future Outlook - The report anticipates that the pharmaceutical industry will continue to see structural growth, particularly in innovative drugs and medical devices, as well as in the aging population and outpatient consumption sectors. It suggests that companies with strong innovative capabilities and those involved in overseas expansion will be key beneficiaries [53][54].